Cancer Clinical Trial
— OVERSEE-IOfficial title:
Identification of Potential Improvements in the Acute Care Pathway for Cancer Patients in the Emergency Department (OVERSEE - I Trial)
NCT number | NCT05974787 |
Other study ID # | 10841 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 29, 2024 |
Est. completion date | July 1, 2024 |
The goal of this single center prospective cross-sectional study is to identify the facilitators and barriers in the course of the disease that starts when symptoms first arise until patients with solid and hematologic malignancies arrive in the emergency department (ED). The main question it aims to answer are: Is there a potential relation between the lag-time and the ED length of stay (LOS) and the chance of admission. Participants will be asked to participate in a one-time interview, that focusses on the pre-admission process.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | July 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months. - Presented at or admitted from the emergency department for the oncology, hematology, neuro- or lung-oncology clinical unit. - Awake and conscious. - Possible to answer questions within 48 hours after presentation at the emergency department (ED). Exclusion Criteria: - <18 years old - Only received a surgical intervention as cancer treatment - Admitted to the ED for the surgical department - Not willing or able to give written informed consent |
Country | Name | City | State |
---|---|---|---|
Netherlands | Erasmus MC | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clusters of facilitators experienced by cancer patients. | Different (sub)clusters of facilitators experienced by cancer patients visiting the emergency department (ED) | Through study completion, an average of 6 months | |
Primary | clusters of barriers experienced by cancer patients. | Different (sub)clusters of barriers experienced by cancer patients visiting the ED | Through study completion, an average of 6 months | |
Secondary | Time-to-speak | The time between the first notice of symptoms and the first time these complaints were spoken out to the primary giver | Through study completion, an average of 6 months | |
Secondary | Time-to-contact | The time between the first time complaints are spoken out and contact is made with a healthcare professional | Through study completion, an average of 6 months | |
Secondary | Time-to-present | The time between the first contact with a healthcare professional and the presentation at the ED | Through study completion, an average of 6 months | |
Secondary | Difference in group average lag-time between day, evening and night | Difference in group average lag-time between day, evening and night | Through study completion, an average of 6 months | |
Secondary | Difference in group average lag-time between weekdays (Monday 08:00 till Friday 23:59) and weekend (Saturday 00:00 and Monday 7:59) | Difference in group average lag-time between weekdays (Monday 08:00 till Friday 23:59) and weekend (Saturday 00:00 and Monday 7:59) | Through study completion, an average of 6 months | |
Secondary | Correlation between number of contacted healthcare providers before presentation at the ED and the lag- time. | Correlation between number of contacted healthcare providers before presentation at the ED and the lag- time. | Through study completion, an average of 6 months | |
Secondary | Willingness to participate | the percentage of people that participated in this study in comparison to the people approached for this study. | Through study completion, an average of 6 months | |
Secondary | Lag-time | The time between the first onset of symptoms and a visit to the ED. | Through study completion, an average of 6 months | |
Secondary | ED length of stay (LOS) | The time a patient spends in the ED | Through study completion, an average of 6 months | |
Secondary | Disposition | The outcome of a visit to the ED, being either admission or home | Through study completion, an average of 6 months | |
Secondary | Patient characteristics | Age, sex, type of cancer, type of complaint, triage category, number of prior visits | Through study completion, an average of 6 months | |
Secondary | Correlation between lag-time and ED-LOS | Correlation between lag-time and ED-LOS | Through study completion, an average of 6 months | |
Secondary | Correlation between lag-time and disposition | Correlation between lag-time and disposition | Through study completion, an average of 6 months | |
Secondary | Correlation between lag-time and patient characteristics | Correlation between lag-time and patient characteristics | Through study completion, an average of 6 months | |
Secondary | ED crowding | Measure of business of the ED, composed of the number of patients in the ED and the color coding used for crowding | Through study completion, an average of 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|